548 related articles for article (PubMed ID: 8930810)
21. Role of phosphodiesterase in regulation of calcium current in isolated cardiac myocytes.
Simmons MA; Hartzell HC
Mol Pharmacol; 1988 Jun; 33(6):664-71. PubMed ID: 2454387
[TBL] [Abstract][Full Text] [Related]
22. Pig aortic endothelial-cell cyclic nucleotide phosphodiesterases. Use of phosphodiesterase inhibitors to evaluate their roles in regulating cyclic nucleotide levels in intact cells.
Souness JE; Diocee BK; Martin W; Moodie SA
Biochem J; 1990 Feb; 266(1):127-32. PubMed ID: 2155604
[TBL] [Abstract][Full Text] [Related]
23. Role of cyclic AMP- and cyclic GMP-phosphodiesterases in the control of cyclic nucleotide levels and smooth muscle tone in rat isolated aorta. A study with selective inhibitors.
Schoeffter P; Lugnier C; Demesy-Waeldele F; Stoclet JC
Biochem Pharmacol; 1987 Nov; 36(22):3965-72. PubMed ID: 2825708
[TBL] [Abstract][Full Text] [Related]
24. Biochemical and pharmacological characterization of cyclic nucleotide phosphodiesterase in airway epithelium.
Rousseau E; Gagnon J; Lugnier C
Mol Cell Biochem; 1994 Nov; 140(2):171-5. PubMed ID: 7898488
[TBL] [Abstract][Full Text] [Related]
25. Dissimilar cyclic nucleotide phosphodiesterase activities in subcellular fractions from normal and SV40-transformed WI-38 fibroblasts.
Nemecek GM; Butcher RW
J Cyclic Nucleotide Res; 1979 Dec; 5(6):449-61. PubMed ID: 94064
[TBL] [Abstract][Full Text] [Related]
26. Cyclic AMP-mediated regulation of vascular smooth muscle cell cyclic AMP phosphodiesterase activity.
Rose RJ; Liu H; Palmer D; Maurice DH
Br J Pharmacol; 1997 Sep; 122(2):233-40. PubMed ID: 9313930
[TBL] [Abstract][Full Text] [Related]
27. Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension.
Murray F; MacLean MR; Pyne NJ
Br J Pharmacol; 2002 Dec; 137(8):1187-94. PubMed ID: 12466227
[TBL] [Abstract][Full Text] [Related]
28. Relationship between inhibition of cardiac muscle phosphodiesterases, changes in cyclic nucleotide levels, and contractile response for CI-914 and other novel cardiotonics.
Weishaar RE; Quade MM; Schenden JA; Evans DB
J Cyclic Nucleotide Protein Phosphor Res; 1985; 10(6):551-64. PubMed ID: 3003170
[TBL] [Abstract][Full Text] [Related]
29. Photoaffinity labelling of cyclic GMP-inhibited phosphodiesterase (PDE III) in human and rat platelets and rat tissues: effects of phosphodiesterase inhibitors.
Tang KM; Jang EK; Haslam RJ
Eur J Pharmacol; 1994 Jun; 268(1):105-14. PubMed ID: 7925608
[TBL] [Abstract][Full Text] [Related]
30. [Kinetic properties and regulation of cyclic nucleotide phosphodiesterases in lymphoid cells].
Azhaeva EV; Severin ES
Bioorg Khim; 1987 Sep; 13(9):1157-63. PubMed ID: 2827690
[TBL] [Abstract][Full Text] [Related]
31. Cellular distribution of phosphodiesterase isoforms in rat cardiac tissue.
Bode DC; Kanter JR; Brunton LL
Circ Res; 1991 Apr; 68(4):1070-9. PubMed ID: 1849058
[TBL] [Abstract][Full Text] [Related]
32. Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors.
Rutten K; Prickaerts J; Hendrix M; van der Staay FJ; Sik A; Blokland A
Eur J Pharmacol; 2007 Mar; 558(1-3):107-12. PubMed ID: 17207788
[TBL] [Abstract][Full Text] [Related]
33. Myofibrillar bound cyclic nucleotide phosphodiesterase in heart and skeletal muscle.
Worby A; Mensah LM; Murray KJ
Biochem Soc Trans; 1992 May; 20(2):129S. PubMed ID: 1327896
[No Abstract] [Full Text] [Related]
34. Cyclic nucleotide-mediated regulation of vascular smooth muscle cell cyclic nucleotide phosphodiesterase activity. Selective effect of cyclic AMP.
Maurice DH
Cell Biochem Biophys; 1998; 29(1-2):35-47. PubMed ID: 9631237
[TBL] [Abstract][Full Text] [Related]
35. Functional and biochemical evidence for diazepam as a cyclic nucleotide phosphodiesterase type 4 inhibitor.
Collado MC; Beleta J; Martinez E; Miralpeix M; Domènech T; Palacios JM; Hernández J
Br J Pharmacol; 1998 Mar; 123(6):1047-54. PubMed ID: 9559885
[TBL] [Abstract][Full Text] [Related]
36. Proteolysis of cyclic AMP phosphodiesterase-II attenuates its ability to be inhibited by compounds which exert positive inotropic actions in cardiac tissue.
Price B; Pyne NJ; Houslay MD
Biochem Pharmacol; 1987 Dec; 36(23):4047-54. PubMed ID: 2825712
[TBL] [Abstract][Full Text] [Related]
37. A comparative kinetic study of bovine calmodulin-dependent cyclic nucleotide phosphodiesterase isozymes utilizing cAMP, cGMP and their 2'-O-anthraniloyl-,2'-O-(N-methylanthraniloyl)-derivatives as substrates.
Grewal J; Karuppiah N; Mutus B
Biochem Int; 1989 Dec; 19(6):1287-95. PubMed ID: 2561449
[TBL] [Abstract][Full Text] [Related]
38. Cyclic nucleotide phosphodiesterases (PDEs) in human osteoblastic cells; the effect of PDE inhibition on cAMP accumulation.
Ahlström M; Pekkinen M; Huttunen M; Lamberg-Allardt C
Cell Mol Biol Lett; 2005; 10(2):305-19. PubMed ID: 16010295
[TBL] [Abstract][Full Text] [Related]
39. Differential modulation of cytokine production by drugs: implications for therapy in heart failure.
Matsumori A; Ono K; Sato Y; Shioi T; Nose Y; Sasayama S
J Mol Cell Cardiol; 1996 Dec; 28(12):2491-9. PubMed ID: 9004165
[TBL] [Abstract][Full Text] [Related]
40. Early increase in lymphocyte cyclic nucleotide phosphodiesterase activity upon mitogenic activation of human peripheral blood mononuclear cells.
Meskini N; Hosni M; Nemoz G; Lagarde M; Prigent AF
J Cell Physiol; 1992 Jan; 150(1):140-8. PubMed ID: 1309823
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
